uMedical
Medicines
Substances
Companies
Statistics
Menu
All medicines
Livmarli
Application withdrawn
Human
Orphan medicine
Details
EMA number
EMEA/H/C/005551
ATC code
A05AX
Authorisation
-
Revision
-
EMA page
Therapeutic indication
Treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2)
MeSH:
Cholestasis, Intrahepatic
Group:
Bile and liver therapy
Active substances
Maralixibat chloride
Marketing Authorisation Holder
Mirum Pharmaceuticals International B.V.
MAH
FGK Representative Service GmbH
MAH
Timeline
Filter by authority:
EMA
Livmarli authorised
9 Dec 2022
authorised
regulatory
Status changed: Authorised → Application withdrawn
17 Dec 2021
status_changed
regulatory
Livmarli | uMedical